Literature DB >> 21330657

Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.

Hiroshi Haruta1, Nobuyuki Ohguro, Minoru Fujimoto, Satoshi Hohki, Fumitaka Terabe, Satoshi Serada, Shintaro Nomura, Kohji Nishida, Tadamitsu Kishimoto, Tetsuji Naka.   

Abstract

PURPOSE. Both Th17 and Th1 cells contribute to experimental autoimmune uveoretinitis (EAU). Interleukin-6 (IL-6) blockade inhibits Th17 differentiation in EAU and potently suppresses ocular inflammation, although its effect on Th1 cells is unknown. To clarify the mechanism of IL-6 blockade, the authors investigated T helper cells with particular focus on Th1 and regulatory T cells (Treg) in EAU of IL-6 gene knockout (KO) mice. METHODS. EAU was induced in wild-type (WT) mice and in mice lacking IL-6 (IL-6KO), IL-17 (IL-17KO), and IFN-γ (GKO) on a C57BL/6 background. Clinical scores of EAU, cytokine levels in supernatants from ocular tissue homogenates, and T helper cell differentiation in lymph nodes in each mouse were examined. To study the roles of Treg cells, EAU was induced in IL-6KO mice treated with anti-CD25 monoclonal antibody (mAb) to deplete Treg cells in vivo. RESULTS. Inflammation was comparable between WT, IL-17KO, and GKO mice but was absent in IL-6KO mice. Th17 and interphotoreceptor retinoid binding protein (IRBP)-specific Th1 cells were increased in GKO and IL-17KO mice, respectively, whereas both populations were reduced in IL-6KO mice. Th1-dominant EAU in IL-17KO mice was suppressed by anti-IL-6R mAb treatment. Treg cell depletion in vivo induced EAU in IL-6KO mice. CONCLUSIONS. After the induction of EAU, IL-6 deficiency resulted in the inhibition of the IRBP-specific Th1 response and enhanced the generation of IRBP-specific Treg cells. Furthermore, Treg was needed to inhibit Th1 responses and ocular inflammation in IL-6KO mice. Protective effects of IL-6 signaling blockade in EAU involve not only Th17 cell inhibition but also IRBP-specific Treg cell promotion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330657     DOI: 10.1167/iovs.10-6272

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  23 in total

Review 1.  Interleukin-6 blockade in ocular inflammatory diseases.

Authors:  M Mesquida; A Leszczynska; V Llorenç; A Adán
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

2.  Preventive effect of chrysin on experimental autoimmune uveitis triggered by injection of human IRBP peptide 1-20 in mice.

Authors:  Xiangda Meng; Sijie Fang; Zhuhong Zhang; Yang Wang; Caiyun You; Jingkai Zhang; Hua Yan
Journal:  Cell Mol Immunol       Date:  2016-03-21       Impact factor: 11.530

Review 3.  IL-6 in inflammation, immunity, and disease.

Authors:  Toshio Tanaka; Masashi Narazaki; Tadamitsu Kishimoto
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-09-04       Impact factor: 10.005

Review 4.  Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature.

Authors:  Sepideh Faez; Ann-Marie Lobo; Sebastian H Unizony; John H Stone; George N Papaliodis; Lucia Sobrin
Journal:  Clin Rheumatol       Date:  2014-04-03       Impact factor: 2.980

5.  Understanding autoimmunity in the eye: from animal models to novel therapies.

Authors:  Rachel R Caspi
Journal:  Discov Med       Date:  2014-03       Impact factor: 2.970

6.  Minimal role of interleukin 6 and toll-like receptor 2 and 4 in murine models of immune-mediated bone marrow failure.

Authors:  Sabrina Solorzano; Jisoo Kim; Jichun Chen; Xingmin Feng; Neal S Young
Journal:  PLoS One       Date:  2021-03-12       Impact factor: 3.240

7.  Effective Arrestin-Specific Immunotherapy of Experimental Autoimmune Uveitis with RTL: A Prospect for Treatment of Human Uveitis.

Authors:  Madison Kyger; Aneta Worley; Jianya Huan; Hugh McDowell; W Clay Smith; Gregory G Burrows; Mary J Mattapallil; Rachel R Caspi; Grazyna Adamus
Journal:  Transl Vis Sci Technol       Date:  2013-02-05       Impact factor: 3.283

Review 8.  Cardiac allograft vasculopathy: current review and future research directions.

Authors:  Jordan S Pober; Sharon Chih; Jon Kobashigawa; Joren C Madsen; George Tellides
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

Review 9.  Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.

Authors:  Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Int J Biol Sci       Date:  2012-10-24       Impact factor: 6.580

10.  STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy.

Authors:  Annalisa Camporeale; Francesca Marino; Anna Papageorgiou; Paolo Carai; Sara Fornero; Steven Fletcher; Brent D G Page; Patrick Gunning; Marco Forni; Roberto Chiarle; Mara Morello; Ole Jensen; Renzo Levi; Stephane Heymans; Valeria Poli
Journal:  EMBO Mol Med       Date:  2013-03-05       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.